drugset
drugset / Trial / NCT03576287

Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis

NCT03576287 ↗

Phase 1/2 Unknown 15 enrolled Tanja Todberg, MD
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the anti-pruritic effect of apremilast in patients with known PN.

Timeline

Start
2017-07-01
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule — Oral

Indications

prurigo nodularis